Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

  • STATUS
    Recruiting
  • participants needed
    240
  • sponsor
    University of Sao Paulo
Updated on 19 February 2024
hypertension
antihypertensive drugs
angiotensin
chest ct
serologic test

Summary

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

Description

Patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classes according to a pre-specified protocol.

Patients are going to be followed during hospital stay for evaluation of clinical endpoints. Also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.

Details
Condition COVID19, Angiotensin II Receptor Antagonist Adverse Reaction
Age 18-80 years
Treatment Renin-angiotensin system inhibitors
Clinical Study IdentifierNCT04493359
SponsorUniversity of Sao Paulo
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Hypertension in use of renin-angiotensin system inhibitors
Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT
Symptoms onset < 96h
Need for hospitalization

Exclusion Criteria

Heart failure
Previous cerebrovascular disease
Previous myocardial infarction
Blood pressure > 180 x 100 mmHg
Need for 3 or more anti-hypertensive classes
Use os spironolactone
Severe pulmonary disease
Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.